A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-14 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Haemophilus influenzae type b (Hib) infection === Naturally acquired disease caused by H. influenzae seems to occur in humans only. In healthy children under the age of 5, H. influenzae type b was responsible for more than 80% of aggressive infections, before the introduction of the [Hib] vaccine. In infants and young children, H. influenzae type b (Hib) causes bacteremia, pneumonia, epiglottitis and acute bacterial meningitis. On occasion, it causes cellulitis, osteomyelitis, and infectious arthritis. It is one cause of neonatal infection. Due to routine use of the Hib vaccine in the US since 1990, the incidence of invasive Hib disease has decreased to 1.3/100,000 in children. However, Hib remains a major cause of lower respiratory tract infections in infants and children in developing countries where the vaccine is not widely used. Unencapsulated H. influenzae strains are unaffected by the Hib vaccine and cause ear infections (otitis media), eye infections (conjunctivitis), and sinusitis in children, and are associated with pneumonia.
Pediatric dentistry (formerly pedodontics in American English or paedodontics in Commonwealth English) is the branch of dentistry dealing with children from birth through adolescence. The specialty of pediatric dentistry is recognized by the American Dental Association, Royal College of Dentists of Canada, and Royal Australasian College of Dental Surgeons.
=== Early life === Frederik Dag Arfst Paulsen was born on 30 October 1950 in Stockholm, Sweden, as a Swedish citizen. His father was Frederik Paulsen Sr, the founder of Ferring Pharmaceuticals. Paulsen grew up in Sweden, with his father and his father's second wife, Dr. Eva Wolf Frandsen – one of the founding researchers at Ferring. He attended school in Sweden and then went on to study chemistry at the Christian Albrecht University in Kiel, (Germany) and business administration at Lund University in Sweden. He received his doctoral degree in Demography from Ecole des Hautes Etudes en Sciences Sociales in Paris, France.
hydrophobic Sometimes used interchangeably with lipophilic. Having a low solubility in or affinity for water or other polar solvents; describing a non-polar molecule, or a moiety or functional group within a molecule, which cannot form energetically favorable interactions with polar compounds and which therefore tends to "avoid" or be repulsed by such compounds, instead clustering together with other hydrophobic molecules or arranging itself in a way that minimizes its exposure to its polar surroundings. This phenomenon is not so much due to the affinity of the hydrophobic molecules for each other as it is a consequence of the strong intermolecular forces that allow polar compounds such as water molecules to bond with each other; hydrophobic species are unable to form alternative bonds of equivalent strength with the polar compounds, hence they tend to be excluded from aqueous solutions by the tendency of the polar solvent to maximize interactions with itself. Hydrophobicity is a major determinant of countless chemical interactions in biological systems, including the spatial conformations assumed by macromolecules such as proteins and lipids, the binding of ligands and substrates to proteins, and the structure and properties of lipid membranes. Contrast hydrophilic.
Sources: en.wikipedia.org
In a solid, shear stress is a function of strain, but in a fluid, shear stress is a function of strain rate. A consequence of this behavior is Pascal's law which describes the role of pressure in characterizing a fluid's state. The behavior of fluids can be described by the Navier–Stokes equations—a set of partial differential equations which are based on:
Absence of antibodies in patients with diagnoses of an autoimmune thyroid in their past would always be suspicious for development to SAT even in the presence of a normal TSH because there is no known recovery from autoimmunity. For clinical interpretation of laboratory results it is important to acknowledge that TSH is released in a pulsatile manner resulting in both circadian and ultradian rhythms of its serum concentrations.
In 2012, newly elected President Enrique Peña Nieto, from the PRI, emphasized that he did not support the involvement of armed American agents in Mexico and was only interested in training Mexican forces in counter-insurgency tactics. At the start of his term, Peña Nieto promised to de-escalate the conflict, focusing on lowering criminal violence rates, as opposed to the previous policy of attacking drug-trafficking organizations by arresting or killing the cartel leaders and intercepting their shipments. His administration's security policy was shaped by Miguel Ángel Osorio Chong (Secretary of the Interior), Jesús Murillo Karam (Attorney General), and Salvador Cienfuegos (National Defense). In the first 14 months of his administration, between December 2012 and January 2014, 23,640 people died in the conflict. During 2012 and 2013, Mexico saw the rise of grupos de autodefensa comunitaria, vigilante self-defense groups in rural communities that took up arms against criminal groups that wanted to impose dominance in their towns, entering a new phase in the Mexican drug war. This strategy, encouraged by Óscar Naranjo, one of Peña Nieto's security advisors, crumbled when autodefensas began having internal struggles and disagreements with the government, as well as infiltration and co-optation by organized crime, causing Peña Nieto's administration to distance from them.
Sources: en.wikipedia.org
=== Depression === Mirtazapine is primarily used for major depressive disorder and other mood disorders. Onset of action appears faster than some selective serotonin reuptake inhibitors and similar to tricyclic antidepressants. In 2010, the National Institute for Health and Care Excellence recommended generic selective serotonin reuptake inhibitors as first-line choices, as they are "equally effective as other antidepressants and have a favourable risk–benefit ratio." For mirtazapine, it found "no difference between mirtazapine and other antidepressants on any efficacy measure, although in terms of achieving remission mirtazapine appears to have a statistical though not clinical advantage. In addition, mirtazapine has a statistical advantage over selective serotonin reuptake inhibitors in terms of reducing symptoms of depression, but the difference is not clinically significant. However, there is strong evidence that patients taking mirtazapine are less likely to leave treatment early because of side effects, although this is not the case for patients reporting side effects or leaving treatment early for any reason." A 2011 Cochrane review comparing mirtazapine to other antidepressants found that while it appeared to have a faster onset in people for whom it worked (measured at two weeks), its efficacy was about the same as other antidepressants after six weeks' use.
Succimer aci or dimercaptosuccinic acid is the organosulfur compound with the formula (HSCH)2(CO2H)2. It is a dicarboxylic acid containing a two thiol functional groups. It is a white solid. Like many dithiols, it is a chelating agent, forming metal thiolate complexes.
Historically, relations between Peru and Bolivia have been cloudy and contradictory, with attempts at reunification and alliances between the two countries due to ethnic and cultural similarities, as well as a series of conflicts that have marked both populations, particularly the Battle of Ingavi, which is seen as the founding war of Bolivia and which has had an impact on the Bolivian imaginary a Peruvian-phobic tendency to see Peru as an expansionist nation that threatens its sovereignty and always opposes Bolivian interests, and a Peruvian reaction to dismiss to Bolivia as the rebel province of Upper Peru that must be annexed, which has generated discord between both peoples, deepened in the actions of their alliance in the War of the Pacific, where they have branded each other as traitors as the reason for their military defeat. All these historical actions have influenced the formation of the national identity in Bolivia with anti-Peruvian overtones. Anti-Peruvian actions in Bolivia can be traced from the beginning of its creation as a country, in 1826 the Bolivians tried to appropriate Arica, Tacna and Tarapacá, signing the sterile Pact of Chuquisaca with a plenipotentiary of Gran Colombia to negotiate limits and the federation of Peru with Charcas, justifying itself in its historical, economic and geographical affinity and stability, since many believed that the division of the "two Perus" was transitory because the great Andean state projected by the Liberator would soon be established.
=== Skin grafts and artificial skin === Two layers of skin created from animal sources as a skin graft is useful in venous leg ulcers. Artificial skin, made of collagen and cultured skin cells, is also used to cover venous ulcers and excrete growth factors to help them heal. A systematic review found that bilayer artificial skin with compression bandaging is useful in the healing of venous ulcers when compared to simple dressings.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.